Our lead compound OT-003
Our lead asset OT-003 is a proprietary small molecule with compelling data across a range of cellular and in vivo models in our indication areas. We are building a pipeline of NCEs based on OT-003’s mechanism, to treat a wide range of neurological disorders.
We perform AI-driven discovery to scale our pipeline of new lead molecules as well as to deliver novel discoveries for external partners.
Our Impact Work
It is part of Pangea’s mission to preserve ethnobotanical knowledge and habitats. We are committed to the Nagoya Protocol on Access and Benefit Sharing and we are working to fulfill the highest ESG standards.